Literature DB >> 24080666

In vitro activity of Ozenoxacin against quinolone-susceptible and quinolone-resistant gram-positive bacteria.

Y López1, M Tato, P Espinal, F Garcia-Alonso, D Gargallo-Viola, R Cantón, J Vila.   

Abstract

In vitro activity of ozenoxacin, a novel nonfluorinated topical (L. D. Saravolatz and J. Leggett, Clin. Infect. Dis. 37:1210-1215, 2003) quinolone, was compared with the activities of other quinolones against well-characterized quinolone-susceptible and quinolone-resistant Gram-positive bacteria. Ozenoxacin was 3-fold to 321-fold more active than other quinolones. Ozenoxacin could represent a first-in-class nonfluorinated quinolone for the topical treatment of a broad range of dermatological infections.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24080666      PMCID： PMC3837899          DOI： 10.1128/AAC.01509-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms.

Authors:  Laurel S Almer; Jennifer B Hoffrage; Erika L Keller; Robert K Flamm; Virginia D Shortridge
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

Review 2.  New quinolone antibiotics: a survey of the literature from 2005 to 2010.

Authors:  Jason A Wiles; Barton J Bradbury; Michael J Pucci
Journal:  Expert Opin Ther Pat       Date:  2010-10       Impact factor: 6.674

3.  In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.

Authors:  Sachin S Bhagwat; Pamela McGhee; Klaudia Kosowska-Shick; Mahesh V Patel; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2008-11-24       Impact factor: 5.191

Review 4.  Antimicrobial resistance in gram-positive bacteria.

Authors:  Louis B Rice
Journal:  Am J Med       Date:  2006-06       Impact factor: 4.965

5.  In vitro induction and selection of fluoroquinolone-resistant mutants of Streptococcus pyogenes strains with multiple emm types.

Authors:  Dewan S Billal; Daniel P Fedorko; S Steve Yan; Muneki Hotomi; Keiji Fujihara; Nancy Nelson; Noboru Yamanaka
Journal:  J Antimicrob Chemother       Date:  2006-10-25       Impact factor: 5.790

6.  Emerging fluoroquinolone resistance in Streptococcus agalactiae in South Korea.

Authors:  M Ki; U Srinivasan; K Y Oh; M Y Kim; J-H Shin; H L Hong; T Dang; Z Britt; B Foxman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-07-04       Impact factor: 3.267

7.  Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones.

Authors:  Louis D Saravolatz; James Leggett
Journal:  Clin Infect Dis       Date:  2003-10-02       Impact factor: 9.079

8.  In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.

Authors:  Yen-Hsu Chen; Chia-Ying Liu; Jang-Jih Lu; Chi-Hsin R King; Po-Ren Hsueh
Journal:  J Antimicrob Chemother       Date:  2009-10-14       Impact factor: 5.790

9.  Correlation between the activity of different fluoroquinolones and the presence of mechanisms of quinolone resistance in epidemiologically related and unrelated strains of methicillin-susceptible and -resistant Staphylococcus aureus.

Authors:  J M Sierra; F Marco; J Ruiz; M T Jiménez de Anta; J Vila
Journal:  Clin Microbiol Infect       Date:  2002-12       Impact factor: 8.067

10.  Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones.

Authors:  M Yamada; J Yoshida; S Hatou; T Yoshida; Y Minagawa
Journal:  Br J Ophthalmol       Date:  2008-05-06       Impact factor: 4.638
View more
  7 in total

Review 1.  Antibiotics in the clinical pipeline at the end of 2015.

Authors:  Mark S Butler; Mark At Blaskovich; Matthew A Cooper
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

2.  Ozenoxacin: A novel topical antibiotic.

Authors:  Parvathy Santhosh; Mithun Harold Thomas
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 Jan-Feb       Impact factor: 2.545

3.  Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo: A Randomized Clinical Trial.

Authors:  Theodore Rosen; Nuria Albareda; Noah Rosenberg; Fernando García Alonso; Sandra Roth; Ilonka Zsolt; Adelaide A Hebert
Journal:  JAMA Dermatol       Date:  2018-07-01       Impact factor: 10.282

4.  Ozenoxacin, a New Effective and Safe Topical Treatment for Impetigo in Children and Adolescents.

Authors:  Antonio Torrelo; Ramon Grimalt; Xavier Masramon; Núria Albareda López; Ilonka Zsolt
Journal:  Dermatology       Date:  2020-01-20       Impact factor: 5.366

5.  Mutant prevention concentration of ozenoxacin for quinolone-susceptible or -resistant Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  Y López; M Tato; D Gargallo-Viola; R Cantón; J Vila; I Zsolt
Journal:  PLoS One       Date:  2019-10-09       Impact factor: 3.240

6.  Safety and efficacy profile of ozenoxacin 1% cream in pediatric patients with impetigo.

Authors:  Adelaide A Hebert; Theodore Rosen; Núria Albareda López; Ilonka Zsolt; Xavier Masramon
Journal:  Int J Womens Dermatol       Date:  2019-11-14

7.  Uptake of Ozenoxacin and Other Quinolones in Gram-Positive Bacteria.

Authors:  Yuly López; Laura Muñoz; Domingo Gargallo-Viola; Rafael Cantón; Jordi Vila; Ilonka Zsolt
Journal:  Int J Mol Sci       Date:  2021-12-12       Impact factor: 5.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.